Latest News

Data from the real-world CEMI-LUNG evaluating cemiplimab in advanced NSCLC were consistent with reports from the EMPOWER-Lung1 study.

A cisplatin-free pembrolizumab regimen yielded 65.1% laryngectomy-free survival rate at 2 years in SMART-KEY, missing significance vs historical controls.

Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.

Risvutatug rezetecan cut the risk of progression or death by 67% vs gemcitabine/docetaxel in heavily pretreated R/R osteosarcoma in ARTEMIS-011.

Two-year MANEUVER data show durable, deepening responses and sustained gains in pain, stiffness, and function with pimicotinib in TGCT.

The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.

At Big Ten CRC, Patricia A. Robinson, MD, discussed institutional and cooperative group strategies that have improved representation in oncology clinical trials.

Biomarker and preclinical data support SEZ6 as a potential therapeutic target in small cell lung cancer management.

Jesus Corral Jaime, MD, reviews real-world survival and response data for cemiplimab monotherapy from the CEMI-LUNG study.

First-line pembrolizumab monotherapy did not significantly improve overall survival vs carboplatin plus paclitaxel at the first analysis in dMMR advanced or recurrent endometrial cancer.

Findings from the phase 1 KANDLELIT-001 study support further investigation of calderasib plus pembrolizumab in KRAS G12C-mutated metastatic NSCLC.

Sacituzumab tirumotecan improved survival vs chemotherapy in patients with advanced or recurrent endometrial cancer after platinum and immunotherapy.

Oral vitamin C improved OS in patients with CCUS or lower-risk myeloid malignancies in the EVITA trial despite missing the clonal growth primary end point.

In KEYNOTE-412, early ctDNA clearance was linked with better survival with pembrolizumab plus chemoradiotherapy in HPV-negative head and neck cancer.

Phase 3 TALAPRO-3 data support the FDA approval of talazoparib/enzalutamide in HRR gene-altered metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.

Initial data from the ROSETTA Lung-107 trial support further study of pumitamig in metastatic NSCLC previously managed with an immunotherapy-based regimen.

More than two-thirds of patients with mismatch repair–deficient locally advanced rectal cancer achieved a clinical complete response with dostarlimab alone.

In the TOP-1 trial, omitting RT and endocrine therapy after breast-conserving surgery yielded a 14.8% 5-year local recurrence risk in women aged 70 and older.

A multidisciplinary panel discusses the effects of GLP-1 RA use during breast cancer care along with insurance denials, costs, and other critical areas.

Data from the phase 3 HARMONi-GI1 trial support first-line ivonescimab plus chemotherapy as a new standard of care in advanced biliary tract cancer.

Based on data from the phase 3 SAFFRON trial, osimertinib plus savolitinib may establish a new global standard of care in this population with EGFR-mutated NSCLC.

Translating laboratory discoveries into clinical benefit increasingly depends on combining genomic profiling with newer tools, including patient-derived functional models and artificial intelligence AI.

Sone-Ve significantly improved OS vs investigator’s choice in previously treated CLDN18.2-positive gastroesophageal carcinoma in CLARITY-Gastric01.

Data from the phase 3 Krascendo 1 trial support divarasib as a new standard in previously treated KRAS G12C–mutated non–small cell lung cancer.

Triplets did not beat pembrolizumab plus lenvatinib in frontline RCC, while belzutifan plus lenvatinib and perioperative pembrolizumab showed benefit.

Long-term PEACE-1 data showed that adding abiraterone acetate plus prednisone to standard of care extended median OS by 1.5 years in de novo metastatic CSPC.

Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.

The phase 3 DeLLphi-305 trial may support tarlatamab plus durvalumab as a new standard-of-care frontline maintenance option in extensive-stage SCLC.

Full INTerpath-001 data at ESMO 2026 detail OS, subgroup, and safety results with intismeran plus pembrolizumab in resected stage IIB to IV melanoma.

In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.

“The more representation, the more people we have participating in clinical trials, the more applicable the data,” said Patricia A. Robinson, MD.